Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial
K Kalantar-Zadeh, GG Schwartz… - Clinical Journal of the …, 2021 - journals.lww.com
Results Median follow-up was 27 months (interquartile range, 20–32 months). In participants
with CKD, apabetalone compared with placebo was associated with fewer major adverse
cardiovascular events (13 events in 124 patients [11%] versus 35 events in 164 patients
[21%]; hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.96) and fewer heart failure–
related hospitalizations (three hospitalizations in 124 patients [3%] versus 14
hospitalizations in 164 patients [9%]; hazard ratio, 0.48; 95% confidence interval, 0.26 to …
with CKD, apabetalone compared with placebo was associated with fewer major adverse
cardiovascular events (13 events in 124 patients [11%] versus 35 events in 164 patients
[21%]; hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.96) and fewer heart failure–
related hospitalizations (three hospitalizations in 124 patients [3%] versus 14
hospitalizations in 164 patients [9%]; hazard ratio, 0.48; 95% confidence interval, 0.26 to …